Santarus Inc (SNTS)

[Tina]

weeeeeeeeeeeeeeeeeeeeee

up AH!!!

5.72 x 5.74

SAN FRANCISCO (MarketWatch) -- Santarus Inc. /quotes/comstock/15*!snts/quotes/nls/snts (SNTS 5.77, +1.48, +34.50%) said Tuesday that the Food and Drug Administration approved over-the-counter heartburn medication Zegerid that uses its technology, triggering a $20 million milestone payment to the biotech company. Shares of Santarus rose 23% to $5.29 a share in after-hours activity. Drug maker Schering-Plough, which was recently acquired by Merck & Co. /quotes/comstock/13*!mrk/quotes/nls/mrk (MRK 37.16, +0.28, +0.76%) , will make milestone and royalty payments to Santarus as a result of the FDA approval.